glp-1 for migraine Migraines and Medications, according to a Neurologist. 🧠👩🏼‍⚕️💖, ⚠️ Disclaimer: This content is educational and informational purposes only. It is not intended as medical advice. , #migraine GLP-1 drugs associated with reduced

Groeneveld, O

FDA warning label updates have progressively acknowledged these additional serious complications: Gallbladder disease (March 2022): Increased risk of cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) requiring surgical removal, with many patients developing symptoms severe enough to necessitate emergency cholecystectomy procedures Intestinal obstruction and ileus (September 2023): FDA acknowledged reports of intestinal blockages that halt normal bowel movement, potentially leading to bowel perforation, sepsis, and death without emergency intervention Pulmonary aspiration during anesthesia (November 2024): Recognition that delayed gastric emptying causes patients to retain food in stomachs far longer than expected, creating aspiration risks when undergoing procedures requiring sedation or general anesthesia Severe gastrointestinal adverse reactions (January 2025): FDA added warnings about serious GI events including severe gastroparesis symptoms and complications requiring hospitalization or surgical intervention The fact that patients who began treatment in 2017, 2018, or 2019 received medications without warnings about ileus, pulmonary aspiration, or severe gastroparesis demonstrates the alleged failure to provide timely and adequate disclosures about serious complications that medical science now clearly links to these medications

Our GLP-1 Medical Weight Loss program is a clinician-led approach to achieving sustainable fat loss and preserving lean muscle mass

Before I explain why polypharmacy is common in diabetes management, let me work through each class

The Precision Peptide Genetic Test from PlexusDx analyzes variants in your GLP1R and GIPR genes that influence how your body responds to GLP-1 therapy, helping your provider make faster, more confident dosing decisions

However, according to data nausea, vomiting, diarrhea, and constipation affect 40%70% of patients on GLP-1 medications